<DOC>
	<DOC>NCT01490658</DOC>
	<brief_summary>This trial is conducted in the United States of America (USA). The aim of this trial is to compare repaglinide and metformin as co-administered tablets and as a combination tablet.</brief_summary>
	<brief_title>Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Healthy male and female volunteers (female not pregnant, lactating or breastfeeding) BMI (Body Mass Index) between 1929 kg/m^2, both inclusive Fasting plasma glucose from 70115 mg/dl Subject is judged to be in good health on the basis of their medical history, physical examination, ECG (electrocardiogram), and routine laboratory data Any clinically significant disease history, in the opinion of the Investigator, of systemic or organ disease Clinically significant abnormalities on prestudy clinical examination or any laboratory measurements during screening Positive results on screening for Hepatitis B surface antigen, Hepatitis C antibody and HIV (human immunodeficiency virus) antibody Positive results on the drug abuse/alcohol screen Any regular use of prescription or nonprescription drugs, including megavitamin or herbal supplement regimens, other than contraceptives, that cannot be stopped at least 1 week prior to Visit 2 (trial product dose administration) and for the duration of the study Subject is currently a smoker (more than one cigarette per day or equivalent) Use of grapefruit or grapefruit juice within 7 days of trial product dose administration Blood donation, surgery or trauma with significant blood loss (500 mL) within the last 2 months prior to dosing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>